Teva introduces generic Avodart

JERUSALEM — Teva Pharmaceuticals on Monday announced the launch of its generic of GlaxoSmithKline’s Avodart (dutsasteride) soft gelatin capsules. The drug, which will be available in 0.5-mg capsules, is indicated for the treatment of benign prostatic hyperplasia in men with an enlarged prostate.

Avodart say U.S. sales of about $467 million as of July 2015, according to IMS Health data.